Alumis (ALMS) Research & Development (2023 - 2026)
Alumis (ALMS) posted quarterly Research & Development of $82.8 million for Q4 2025, down 5.07% year-over-year from $87.2 million in Q4 2024, and down 15.38% quarter-over-quarter from $97.8 million in Q3 2025.
Analysis
Alumis (ALMS) Research & Development (2023 - 2026) Analysis & Trends
Alumis (ALMS) has reported Research & Development for 3 consecutive years, with $82.8 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Research & Development fell 5.07% year-over-year to $82.8 million; the TTM figure through Dec 2025 stood at $386.0 million (up 45.36% YoY), while the FY2025 annual figure was $386.0 million, up 45.36% from the prior year.
- Research & Development fell to $82.8 million in Q4 2025 per ALMS's latest filing, from $97.8 million in the prior quarter.
- Across five years, Research & Development topped out at $108.8 million in Q2 2025 and bottomed at $32.8 million in Q2 2023.
- Historically, Research & Development has averaged $68.8 million across 3 years, with a median of $82.8 million in 2025.
- Annual changes were most pronounced in 2024 — Research & Development surged 152.0% — and 2025, when it declined 5.07%.
- Alumis' Research & Development stood at $34.6 million in 2023, then jumped by 152.0% to $87.2 million in 2024, then slipped by 5.07% to $82.8 million in 2025.
- Business Quant data shows ALMS's Research & Development at $82.8 million in Q4 2025, $97.8 million in Q3 2025, and $108.8 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | -486.00 Mn |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn | 651.00 Mn |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | 394.92 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 612.28 Mn |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn | 413.13 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 97.90 Mn |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Alumis | 1.43 Bn | 924.74 Mn | - | 85.34 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 85.34 Mn |
| Dec 31, 2025 | 82.79 Mn |
| Sep 30, 2025 | 97.84 Mn |
| Jun 30, 2025 | 108.76 Mn |
| Mar 31, 2025 | 96.62 Mn |
| Dec 31, 2024 | 87.20 Mn |
| Sep 30, 2024 | 87.82 Mn |
| Jun 30, 2024 | 48.57 Mn |
| Mar 31, 2024 | 41.96 Mn |
| Dec 31, 2023 | 34.61 Mn |
| Sep 30, 2023 | 37.79 Mn |
| Jun 30, 2023 | 32.85 Mn |